Sawatari Yoh, Marx Robert E
Division of Oral and Maxillofacial Surgery, University of Miller Miami School of Medicine, 9380 SW 150th Street, Miami, FL 33157, USA.
Oral Maxillofac Surg Clin North Am. 2007 Nov;19(4):487-98, v-vi. doi: 10.1016/j.coms.2007.07.003.
Bisphosphonate-induced osteonecrosis of the jaws is the correct term for this real drug complication that most dental practitioners face. All nitrogen-containing bisphosphonates pose a risk, which is related to the route of administration, the potency of the bisphosphonate, and the duration of use. Although intravenous bisphosphonate-induced osteonecrosis of the jaws is mostly permanent, most cases can be prevented or managed if they develop, with only a few cases requiring resection for resolution. Oral bisphosphonate-induced osteonecrosis of the jaws also can be prevented with knowledge of the risk level related to the duration of use and the C-terminal telopeptide blood test results. Most cases can be resolved with a drug holiday either spontaneously or via straightforward débridement.
双膦酸盐导致的颌骨坏死是大多数牙科从业者面临的这种真实药物并发症的正确术语。所有含氮双膦酸盐都有风险,这与给药途径、双膦酸盐的效力和使用持续时间有关。虽然静脉注射双膦酸盐导致的颌骨坏死大多是永久性的,但大多数病例如果发生可以预防或处理,只有少数病例需要切除才能解决。了解与使用持续时间相关的风险水平和C端肽血液检测结果,也可以预防口服双膦酸盐导致的颌骨坏死。大多数病例可以通过停药自行解决,或者通过简单的清创解决。